# EDGAR Filing Document

**Accession Number:** 0001717580
**File Stem:** 0001104659-23-006235
**Filing Date:** 2023-1
**Character Count:** 7656
**Document Hash:** 5df584106402a9dd2510ea47fd19b9ca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-006235.hdr.sgml**: 20230124

**ACCESSION NUMBER**: 0001104659-23-006235

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230120

**FILED AS OF DATE**: 20230124

**DATE AS OF CHANGE**: 20230124

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Palczuk Linda
- **CENTRAL INDEX KEY:** 0001717580

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37977
- **FILM NUMBER:** 23548838

**MAIL ADDRESS:**
- **STREET 1:** 7015 ALBERT EINSTEIN DRIVE
- **CITY:** COLUMBIA
- **STATE:** MD
- **ZIP:** 21046
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVADEL PHARMACEUTICALS PLC
- **CENTRAL INDEX KEY:** 0001012477
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
- **STREET 2:** BALLYCOOLIN
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** 15
- **BUSINESS PHONE:** 636-449-1830

**MAIL ADDRESS:**
- **STREET 1:** 16640 CHESTERFIELD GROVE ROAD
- **STREET 2:** SUITE 200
- **CITY:** CHESTERFIELD
- **STATE:** MO
- **ZIP:** 63005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLAMEL TECHNOLOGIES SA
- **DATE OF NAME CHANGE:** 19960422

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Palczuk Linda<br><sub>(Last) (First) (Middle)</sub><br>C/O AVADEL PHARMACEUTICALS PLC<br>10 EARLSFORT TERRACE<br><sub>(Street)</sub><br>DUBLIN 2, L2 D02 T380<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>AVADEL PHARMACEUTICALS PLC [ AVDL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $2.03 | 2023-01-20 |  | G | V |  | 60000 | <sup>(1)</sup> | 2029-08-07 | ADSs<sup>(2)</sup> | 60000 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $2.03 |  |  |  |  |  |  | <sup>(1)</sup> | 2029-08-07 | ADSs<sup>(2)</sup> | 60000 |  | 60000 | I | By Trust<sup>(3)</sup> |
| Stock Option (Right to Buy) | $8.48 | 2023-01-20 |  | G | V |  | 42000 | <sup>(4)</sup> | 2030-08-07 | ADSs<sup>(2)</sup> | 42000 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $8.48 |  |  |  |  |  |  | <sup>(4)</sup> | 2030-08-07 | ADSs<sup>(2)</sup> | 42000 |  | 42000 | I | By Trust<sup>(3)</sup> |
| Stock Option (Right to Buy) | $8.07 | 2023-01-20 |  | G | V |  | 42000 | <sup>(1)</sup> | 2031-08-03 | ADSs<sup>(2)</sup> | 42000 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $8.07 |  |  |  |  |  |  | <sup>(1)</sup> | 2031-08-03 | ADSs<sup>(2)</sup> | 42000 |  | 42000 | I | By Trust<sup>(3)</sup> |
| Stock Option (Right to Buy) | $4.79 | 2023-01-20 |  | G | V |  | 42000 | <sup>(5)</sup> | 2032-08-03 | ADSs<sup>(2)</sup> | 42000 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $4.79 |  |  |  |  |  |  | <sup>(5)</sup> | 2032-08-03 | ADSs<sup>(2)</sup> | 42000 |  | 42000 | I | By Trust<sup>(3)</sup> |

---

### Footnotes:

(1) These options are fully vested and exercisable as of the date hereof.

(2) The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

(3) On January 20, 2023, the Reporting Person transferred an aggregate of 186,000 options to a revocable trust of which the Reporting Person is trustee.

(4) These options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date, subject to the Reporting Person's continued service at each such vesting date.

(5) These options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time.

**Signature:** /s/ Jerad G. Seurer, as attorney-in-fact  
**Date:** 2023-01-24

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**